Physician profile
Tareva Warrick-Stone
NPI 1255827325
$32,271.23
in general payments reported to CMS, 2019-2025
13 companies · $32K in 2025
The $32K reported for 2025 was more than what 99% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15.00 · 2021: $211 · 2022: $46.91 · 2023: $50.75 · 2024: $25.82 · 2025: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $32K · Food and Beverage: $291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $31,707.00 |
| Food and Beverage | $291.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $31,707.00 | 2025 | |
| Abbvie INC. | $123.80 | 2025 | |
| Glaxosmithkline, LLC. | $100.01 | 2021 | |
| Braeburn INC. | $91.05 | 2025 | Brixadi |
| Bayer Healthcare Pharmaceuticals INC. | $50.75 | 2023 | |
| Lilly USA, LLC | $44.09 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.02 | 2021-2022 | |
| Indivior INC. | $25.82 | 2024 | Sublocade |
| Merck Sharp & Dohme LLC | $20.37 | 2021 | |
| Amgen INC. | $19.55 | 2021 | |
| Novo Nordisk INC | $16.90 | 2022 | |
| Pfizer INC. | $14.79 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $13.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tareva Warrick-Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.